DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+9.26%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$398M
AUM Growth
+$398M
(+5.5%)
Cap. Flow
+$11.1M
Cap. Flow
% of AUM
2.78%
Top 10 Holdings %
Top 10 Hldgs %
51.36%
Holding
92
New
12
Increased
23
Reduced
18
Closed
5
Top Buys
| 1 |
Adicet Bio
ACET
|
$6.24M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
$4.72M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$4.27M |
| 4 |
Axogen
AXGN
|
$3.11M |
| 5 |
MEI Pharma
MEIP
|
$3M |
Top Sells
| 1 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$11.8M |
| 2 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$4.13M |
| 3 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
$2.74M |
| 4 |
AFMD
Affimed
AFMD
|
$2.17M |
| 5 |
Galapagos
GLPG
|
$1.93M |
Sector Composition
| 1 | Healthcare | 94.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
OTIC
26
DELISTED
Otonomy, Inc.
OTIC
| $4.58M | 1.15% |
2,200,297
-179,095
| -8% | -$373K |
|
|
NTUS
27
DELISTED
Natus Medical Inc
NTUS
| $4.52M | 1.14% |
190,635
+94,982
| +99% | +$2.25M |
|
28
Accuray
ARAY
$165M
| $4.49M | 1.13% |
941,800
| – | – |
|
|
PRDS
29
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $3.82M | 0.96% |
233,500
-66,450
| -22% | -$1.09M |
|
|
FSTX
30
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $3.48M | 0.88% |
693,785
| – | – |
|
31
Alector
ALEC
$282M
| $3.21M | 0.81% |
155,247
+47,835
| +45% | +$988K |
|
|
AFMD
32
DELISTED
Affimed
AFMD
| $3.15M | 0.79% |
571,282
-393,575
| -41% | -$2.17M |
|
|
33
Axogen
AXGN
$718M
| $3.11M | 0.78% |
+332,103
| New | +$3.11M |
|
34
KalVista Pharmaceuticals
KALV
$713M
| $2.52M | 0.63% |
190,663
+1,500
| +0.8% | +$19.8K |
|
|
ITOS
35
DELISTED
iTeos Therapeutics
ITOS
| $2.52M | 0.63% |
54,090
-28,971
| -35% | -$1.35M |
|
|
36
Galapagos
GLPG
$2.06B
| $2.35M | 0.59% |
42,675
-35,000
| -45% | -$1.93M |
|
37
Biomea Fusion
BMEA
$114M
| $2.34M | 0.59% |
+313,923
| New | +$2.34M |
|
38
Rigel Pharmaceuticals
RIGL
$710M
| $2.33M | 0.59% |
879,000
+70,000
| +9% | +$185K |
|
|
TPTX
39
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $2.22M | 0.56% |
46,452
+4,500
| +11% | +$215K |
|
40
Athira Pharma
ATHA
$15.5M
| $2.1M | 0.53% |
160,983
| – | – |
|
41
Viking Therapeutics
VKTX
$3.02B
| $2.06M | 0.52% |
447,400
| – | – |
|
|
AERI
42
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $2.03M | 0.51% |
289,040
| – | – |
|
43
Cogent Biosciences
COGT
$1.83B
| $1.92M | 0.48% |
223,554
| – | – |
|
44
89bio
ETNB
$1.37B
| $1.89M | 0.48% |
144,653
+18,001
| +14% | +$235K |
|
|
KNTE
45
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $1.89M | 0.47% |
106,453
| – | – |
|
|
MREO
46
Mereo BioPharma
MREO
$275M
| $1.8M | 0.45% |
1,126,613
| – | – |
|
|
RGLS
47
DELISTED
Regulus Therapeutics
RGLS
| $1.75M | 0.44% |
+5,555,555
| New | +$1.75M |
|
48
Venus Concept
VERO
$4.07M
| $1.66M | 0.42% |
975,687
-137,541
| -12% | -$234K |
|
49
Century Therapeutics
IPSC
$40.4M
| $1.59M | 0.4% |
100,135
+20,135
| +25% | +$319K |
|
50
Kura Oncology
KURA
$732M
| $1.55M | 0.39% |
110,829
+10,000
| +10% | +$140K |
|